Heptares Therapeutics Ltd.

Heptares Therapeutics has a technology that stabilizes GPCRs when they are removed from the cell membrane--overcoming one of the field's traditional challenges and allowing scientists to more easily study the receptors' structure and how ligands attach to and detach from them. Heptares' trick: introducing point mutations into GPCR genes that make them less flexible and likely to deform when removed from the cell wall. Heptares is going after small-molecule and antibody drugs in CNS and metabolic diseases.